Novartis and Novavax both say they're now able to develop new immunizations within months of a viral strain's identification and sequencing.
Winter's coming, along with warnings that new cases of H7N9 bird flu in China warrant a global pandemic alert. While the most recent pandemic alarms have fizzled out without any major outbreaks of a lethal virus, the federal government has been supporting work on new vaccine technologies.
The reemergence of H7N9 in China during the past month has reinforced the need for a vaccine. Candidates from Chinese and Taiwanese manufacturers have grabbed the headlines recently, but now a U.S. player, Novavax, has joined the race with positive Phase I data.
H7N9 activity has slowed dramatically, but health authorities fear it will return in China and possibly beyond as temperatures cool. If this happens, the advancement of vaccines should strengthen the ability of healthcare systems to protect people.
The deal has the backing of the three largest shareholders, and Novavax expects to close the takeover by the end of next month. With the deal, Novavax gets ownership of a proprietary adjuvant technology it can use in vaccine candidates for pandemic flu, rabies, respiratory syncytial virus in the elderly, foot-and-mouth and other diseases.
he vaccine works by immunizing women in their childbearing years, causing them to pass on protective antibodies to guard infants. Now it's on to a pivotal trial.
Some 19 months following his abrupt departure from the helm at Novavax, Rahul Singhvi is back with a new start-up with plans to develop a trio of armed-antibody cancer drugs.
Novavax enjoyed a bump in its stock--a climb of 4.9%--after reporting positive results from two Phase I trials of its avian influenza vaccine candidate, Bloomberg reports. Novavax closed Friday at $2.35; shares have risen 87% this year.
Novavax, CPL Biologicals and the International Centre for Genetic Engineering and Biotechnology will team up to develop a malaria vaccine in India.
Novavax saw a climb in its share value on the announcement that it has started enrollment of a Phase I clinical trial of its A/H5N1 vaccine to prevent bird flu.